Top 10 Companies in the (S)-(-)-Glycidol (CAS No. 60456-23-7) Market (2026): Market Leaders Driving Global Innovation

MARKET INSIGHTS

Global (S)-(-)-Glycidol (CAS No. 60456-23-7) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 6.4% during the forecast period.

(S)-(-)-Glycidol is a chiral epoxide compound – a colorless, water‑miscible liquid with high optical purity – widely recognized for its reactivity and versatility as a synthetic building block in fine chemical manufacturing. As the (S)-enantiomer of glycidol, it serves a critical role in asymmetric synthesis, enabling the production of enantiomerically enriched pharmaceuticals, agrochemicals, and specialty chemical intermediates. Its reactive epoxide ring makes it a valuable precursor in the synthesis of beta‑blockers, antifungal agents, and other active pharmaceutical ingredients (APIs) where stereochemical precision is essential.

(S)-(-)-Glycidol (CAS No. 60456-23-7) Market – View in Detailed Research Report

1. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: High‑purity (S)-(-)-Glycidol for pharmaceutical intermediates

Merck KGaA has a long history of supplying high‑quality chiral building blocks. Leveraging proprietary asymmetric epoxidation and kinetic resolution technologies, the company delivers (S)-(-)-Glycidol with enantiomeric excess exceeding 99%. Its robust cGMP production facilities support large‑scale API synthesis for beta‑blockers, antivirals, and nucleoside analogues.

Sustainability & Growth Initiatives:

• Investment in biocatalytic processes to reduce solvent usage
• Carbon‑neutral production targets by 2030
• Partnerships with academic institutions for green chemistry research

2. Tokyo Chemical Industry Co., Ltd.

Headquarters: Tokyo, Japan
Key Offering: Enantiomerically enriched glycidol for fine chemicals and pharmaceuticals

TCI offers a range of (S)-(-)-Glycidol grades, from laboratory to industrial. The company’s focus on advanced asymmetric synthesis, including the Sharpless epoxidation, ensures consistent supply of high‑purity material for agrochemical and specialty polymer applications.

Sustainability & Growth Initiatives:

• Implementation of zero‑waste manufacturing lines
• Development of renewable feedstock‑based synthesis routes
• Active participation in EU green chemistry initiatives

3. Thermo Fisher Scientific Inc.

Headquarters: Waltham, USA
Key Offering: Custom chiral synthesis and supply of (S)-(-)-Glycidol

Thermo Fisher’s integrated platform combines chemical synthesis with analytical services, enabling rapid turnaround for custom API intermediates. The company’s expertise in biocatalytic resolution enhances its competitive edge in the chiral building block market.

Sustainability & Growth Initiatives:

• Adoption of renewable energy in manufacturing plants
• Life‑cycle assessment of chiral intermediates
• Collaboration with pharmaceutical CROs for sustainable synthesis

4. Kaneka Corporation

Headquarters: Tokyo, Japan
Key Offering: High‑purity (S)-(-)-Glycidol for specialty chemicals

Kaneka’s focus on high‑value specialty chemicals includes the production of chiral epoxides. The company’s process chemistry emphasizes low‑energy consumption and high atom‑efficiency, aligning with global green chemistry trends.

Sustainability & Growth Initiatives:

• Reduction of hazardous waste by 30% by 2028
• Development of solvent‑free synthesis protocols
• Participation in global sustainability reporting frameworks

5. Biosynth AG

Headquarters: Basel, Switzerland
Key Offering: Enzymatic production of (S)-(-)-Glycidol

Biosynth AG pioneers biocatalytic routes for chiral epoxides, using engineered epoxide hydrolases and lipases to achieve high enantioselectivity under mild conditions. The company supplies both laboratory and industrial grades, supporting both research and large‑scale API synthesis.

Sustainability & Growth Initiatives:

• Zero‑solvent manufacturing processes
• Carbon‑offset programs for chemical production
• Investment in enzyme engineering for cost reduction

6. Combi-Blocks Inc.

Headquarters: Irvine, USA
Key Offering: Custom chiral building blocks including (S)-(-)-Glycidol

Combi-Blocks offers rapid custom synthesis services for chiral intermediates. Their flexible production platform allows quick scale‑up for pharmaceutical development, making them a preferred partner for emerging drug candidates.

Sustainability & Growth Initiatives:

• Implementation of green chemistry principles in all syntheses
• Use of recyclable solvents and catalysts
• Carbon‑neutral logistics for product delivery

7. Oakwood Products, Inc.

Headquarters: Newark, USA
Key Offering: High‑purity (S)-(-)-Glycidol for fine chemicals

Oakwood Products focuses on high‑purity specialty chemicals. Their rigorous quality control ensures consistent optical purity, making them a trusted supplier for pharmaceutical and agrochemical manufacturers.

Sustainability & Growth Initiatives:

• Energy‑efficient production lines
• Waste‑minimization strategies
• Support for circular economy initiatives in the chemical sector

8. Apollo Scientific Ltd.

Headquarters: London, UK
Key Offering: Custom synthesis of (S)-(-)-Glycidol and related chiral intermediates

Apollo Scientific specializes in rapid, scalable synthesis of chiral building blocks. Their modular synthesis platform reduces lead times and supports continuous manufacturing for API production.

Sustainability & Growth Initiatives:

• Adoption of renewable feedstocks
• Reduction of hazardous waste streams
• Carbon‑neutral packaging solutions

9. Enamine Ltd.

Headquarters: Kyiv, Ukraine
Key Offering: High‑purity (S)-(-)-Glycidol for medicinal chemistry research

Enamine provides a range of chiral epoxides to support drug discovery. Their emphasis on rapid delivery and flexible order sizes caters to CROs and academic labs worldwide.

Sustainability & Growth Initiatives:

• Use of green solvents in synthesis
• Energy‑efficient laboratory operations
• Collaboration with international sustainability programs

10. Pharmablock Sciences Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Large‑scale production of (S)-(-)-Glycidol for API intermediates

Pharmablock Sciences leverages advanced asymmetric synthesis to meet the growing demand for chiral intermediates in the rapidly expanding Chinese pharmaceutical market. Their production capacity supports both domestic and export markets.

Sustainability & Growth Initiatives:

• Implementation of energy‑saving technologies
• Reduction of volatile organic compound emissions
• Integration of circular waste management systems

Download FREE Sample Report

(S)-(-)-Glycidol (CAS No. 60456-23-7) Market – View in Detailed Research Report

Market Outlook 2026‑2034

The (S)-(-)-Glycidol market is poised for steady growth, driven by the increasing demand for enantiopure drug intermediates and the expanding pipeline of stereospecific APIs. With a projected CAGR of 6.4%, the market is expected to reach USD 52.6 million by 2034. Key growth drivers include the adoption of asymmetric synthesis across fine chemicals, regulatory mandates for single‑enantiomer drugs, and the expansion of specialty polymer applications.

Future Trends and Emerging Opportunities

• Advancements in biocatalytic production routes to lower cost and improve sustainability
• Growth of the Asia‑Pacific fine chemical manufacturing infrastructure, enhancing local supply chains
• Increasing use of (S)-(-)-Glycidol in chiral polymer and material science, expanding beyond pharmaceuticals
• Enhanced regulatory focus on chirality and purity, driving higher quality standards